Previous Article | Next Article ![]()
Journal of Virology, March 2007, p. 2307-2317, Vol. 81, No. 5
0022-538X/07/$08.00+0 doi:10.1128/JVI.02063-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
,
Molecular and Integrative Neurosciences Department, The Scripps Research Institute, La Jolla, California 92037,1 La Jolla Institute of Allergy and Immunology, La Jolla, California 92121,2 Pharmexa-Epimmune, San Diego, California 921213
Received 20 September 2006/ Accepted 1 December 2006
The consequences of human lymphocytic choriomeningitis virus (LCMV) infection can be severe, including aseptic meningitis in immunocompetent individuals, hydrocephalus or chorioretinitis in fetal infection, or a highly lethal outcome in immunosuppressed individuals. In murine models of LCMV infection, CD8+ T cells play a primary role in providing protective immunity, and there is evidence that cellular immunity may also be important in related arenavirus infections in humans. For this reason, we sought to identify HLA-A2 supertype-restricted epitopes from the LCMV proteome and evaluate them as vaccine determinants in HLA transgenic mice. We identified four HLA-A*0201-restricted peptidesnucleoprotein NP69-77, glycoprotein precursor GPC10-18, GPC447-455, and zinc-binding protein Z49-58that displayed high-affinity binding (
275 nM) to HLA-A*0201, induced CD8+ T-cell responses of high functional avidity in HLA-A*0201 transgenic mice, and were naturally processed from native LCMV antigens in HLA-restricted human antigen presenting cells. One of the epitopes (GPC447-455), after peptide immunization of HLA-A*0201 mice, induced CD8+ T cells capable of killing peptide-pulsed HLA-A*0201-restricted target cells in vivo and protected mice against lethal intracranial challenge with LCMV.
Published ahead of print on 13 December 2006.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»